This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: Due to resistance to all classes of anti-HIV drugs and drug toxicity, there is a need for the discovery and development of new anti-HIV drugs. METHODS: HIV-1 inhibitors were identified and biologically characterized for mechanism of action. RESULTS: We identified a dibenzocyclooctadiene lignan, termed HDS2 that possessed anti-HIV activity against a wide variety of viral strains with EC50 values in the 1-3 µM range. HDS2 was shown to act as an NNRTI by qPCR and in vitro enzyme assays. CONCLUSIONS: This compound provides a new scaffold for further optimization of activity through structure-guided design.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Han et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: